AbbVie doubles down on cystic fibrosis R&D, adding a new drug to the pipeline as Vertex seals its domination of the field with Trikafta OK
AbbVie turned some heads last fall when the pharma giant announced plans to scoop up a portfolio of cystic fibrosis drugs from their partners at Galapagos in a $245 million deal — after the latest data came out looking particularly weak compared to what Vertex was reporting. Still ignoring the doubters, AbbVie is doubling down, bringing in a preclinical CFTR potentiator compound from the Cystic Fibrosis Foundation to sharpen its combo approach.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.